Advertisement
Sedana Medical AB (publ) (7D2A.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Follow
As of 09:15AM CET. Market open.
| Previous Close | 0.9030 |
| Open | 0.8930 |
| Bid | 0.8840 x N/A |
| Ask | 0.9490 x N/A |
| Day's Range | 0.8930 - 0.8930 |
| 52 Week Range | 0.8930 - 2.3900 |
| Volume | |
| Avg. Volume | 3,264 |
| Market Cap | 93.26M |
| Beta (5Y Monthly) | 0.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0500 |
| Earnings Date | Feb 13, 2025 - Feb 17, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GuruFocus.com
Sedana Medical AB (FRA:7D2A) Q3 2024 Earnings Call Highlights: Record Sales and Strategic Moves ...
Despite challenges, Sedana Medical AB (FRA:7D2A) reports its highest Q3 net sales and raises full-year sales guidance, driven by strong market performance and strategic acquisitions.
PR NewswireSedana Medical completes patient recruitment for its clinical program in the US
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 2 phase III clinical trial in the United States. Earlier this spring, Sedana Medical reported the completion of enrolment to the parallel phase III clinical trial INSPiRE-ICU 1. The company anticipates topline results from both trials in the second half of 2024, with a planned New Drug Application (NDA) submission in the first quarter of 2025.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.